Pathwork tissue test passes muster in multi-center investigation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 4
Volume 18
Issue 4

A multi-institutional group has validated a predefined 1,550-gene expression profile for identifying tumor tissue of origin. Malignancies found in unexpected locations, or with poorly differentiated morphologies, can pose a challenge for tissue of origin determination.

A multi-institutional group has validated a predefined 1,550-gene expression profile for identifying tumor tissue of origin. Malignancies found in unexpected locations, or with poorly differentiated morphologies, can pose a challenge for tissue of origin determination.

Current histologic and imaging techniques fail to yield definitive identification, according to lead author Federico A. Monzon, MD and colleagues.

The group evaluated 547 frozen specimens representing 15 tissues of origin with the Pathwork Tissue of Origin Test, in which microarray technology measures gene expression pattern.

According to the study results, the test had an overall sensitivity of 87.8% and overall specificity of 99.4%. Performance within the subgroup of metastatic tumors (n = 258) was found to be slightly lower than that of the poorly differentiated and undifferentiated primary tumor subgroup, 84.5% and 90.7%, respectively (J Clin Oncol online, March 30, 2009).

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.